Moderna is deprioritizing its flu/COVID combination vaccine in younger adults amid a push to cut about $1.5 billion from its ...

On a Thursday conference call with investors, Moderna CFO Jamey Mock outlined a roadmap for the mRNA specialist to lower its ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Moderna’s vaccine candidate includes three different norovirus types. “It would be great if there were some conserved regions of the norovirus protein that could be targeted, but that’s not ...

Moderna could have many products on the market and in a variety of areas. Among these, we may find a cytomegalovirus (CMV) vaccine, a personalized cancer vaccine, and a norovirus vaccine.

Moderna MRNA is expected to report first-quarter 2025 earnings on May 1, before the opening bell. The company’s earnings beat ...

Jefferies analysts said Moderna’s first quarter was “in line,” with a miss on revenue offset by a beat on earnings per share.

Why it matters: With $8.4 billion in cash left at the end of the quarter, investors are closely watching Moderna's strategy for focusing its remaining covid vaccine profits from the pandemic on ...

Q1 2025 Earnings Call Transcript May 1, 2025 Moderna, Inc. beats earnings expectations. Reported EPS is $-2.52, expectations were $-2.92. Operator: Good day, and thank you for standing by. Welcome to ...